Literature DB >> 31662531

T-Lymphocyte Activation Is Correlated With the Presence of Anti-EBV in Patients With Laryngeal Squamous Cell Carcinoma.

Janusz Klatka1, Anna Hymos1, Anna Szkatuła-Łupina1, Ewelina Grywalska2, Barbara Klatka1, Michał Terpiłowski1, Andrzej Stepulak3.   

Abstract

BACKGROUND/AIM: Chronic viral infection is an important risk factor in the development of cancer. Failure of immune response to clear the oncogenic infection can facilitate cancer progression. The aim of the present study was to analyze early and late activation of T-lymphocytes related to Epstein-Barr virus (EBV) infection by the expression of markers of activation (CD69, CD25) on the surface of T-lymphocytes (CD3+, CD4+, CD8+) in patients bearing laryngeal cancer according to absence/presence immunoglobulin G antibodies to EBV nuclear antigen (EBNA1).
MATERIALS AND METHODS: Thirty-three patients with laryngeal squamous cell carcinoma (LC) and 20 volunteers without cancer (control group) were enrolled in the study. Peripheral blood samples were collected from every individual. The markers of activation of T-lymphocytes were determined by flow cytometry, whereas commercial immunoenzymatic assay kits were used for detection of anti-viral capsid antigen (VCA) IgM, anti-VCA IgG, and anti-EBNA1 IgG.
RESULTS: Increased early activation of CD8+ and CD4+ T-lymphocytes was found in patients with LC. There was a significantly higher proportion of CD4+ and CD8+T-lymphocytes expressing CD69 antigen in patients with LC compared to the control group. The proportion of CD4+ CD25+ T-lymphocytes in patients with LC positive for anti-EBNA1 IgG and anti-VCA IgM was lower compared to patients without antibodies to VCA IgM.
CONCLUSION: The dysfunction of immune response in larynx cancer patients could be associated with EBV infection. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Laryngeal squamous cell carcinoma; T-lymphocyte activation; antibodies to EBV

Mesh:

Substances:

Year:  2019        PMID: 31662531      PMCID: PMC6899120          DOI: 10.21873/invivo.11697

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  34 in total

Review 1.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

2.  Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.

Authors:  Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector
Journal:  Oral Oncol       Date:  2017-12-23       Impact factor: 5.337

3.  Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.

Authors:  K C Allen Chan; John K S Woo; Ann King; Benny C Y Zee; W K Jacky Lam; Stephen L Chan; Sam W I Chu; Constance Mak; Irene O L Tse; Samantha Y M Leung; Gloria Chan; Edwin P Hui; Brigette B Y Ma; Rossa W K Chiu; Sing-Fai Leung; Andrew C van Hasselt; Anthony T C Chan; Y M Dennis Lo
Journal:  N Engl J Med       Date:  2017-08-10       Impact factor: 91.245

Review 4.  NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management.

Authors:  S E Straus; J I Cohen; G Tosato; J Meier
Journal:  Ann Intern Med       Date:  1993-01-01       Impact factor: 25.391

5.  Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.

Authors:  P J Wingate; K A McAulay; I C Anthony; D H Crawford
Journal:  J Med Virol       Date:  2009-05       Impact factor: 2.327

6.  Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells.

Authors:  Mairaj Ahmed Ansari; Vivek Vikram Singh; Sujoy Dutta; Mohanan Valiya Veettil; Dipanjan Dutta; Leela Chikoti; Jie Lu; David Everly; Bala Chandran
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

7.  Epstein-Barr virus and thyroid cancer: The role of viral expressed proteins.

Authors:  Mohsen Moghoofei; Shayan Mostafaei; Abolfazl Nesaei; Ashkan Etemadi; Javid Sadri Nahand; Hamed Mirzaei; Bahman Rashidi; Farhad Babaei; Niloofar Khodabandehlou
Journal:  J Cell Physiol       Date:  2018-10-26       Impact factor: 6.384

8.  Serum EBV antibodies and LMP-1 in Polish patients with oropharyngeal and laryngeal cancer.

Authors:  Sylwia Fołtyn; Małgorzata Strycharz-Dudziak; Bartłomiej Drop; Anastazja Boguszewska; Małgorzata Polz-Dacewicz
Journal:  Infect Agent Cancer       Date:  2017-05-30       Impact factor: 2.965

9.  Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.

Authors:  Huan Zhou; Shun Tan; Hong Li; Xiangtao Lin
Journal:  Mol Med Rep       Date:  2019-01-22       Impact factor: 2.952

Review 10.  Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells.

Authors:  Chi Man Tsang; Wen Deng; Yim Ling Yip; Mu-Sheng Zeng; Kwok Wai Lo; Sai Wah Tsao
Journal:  Chin J Cancer       Date:  2014-09-16
View more
  2 in total

1.  Antibodies as biomarkers for cancer risk: a systematic review.

Authors:  Maria J Monroy-Iglesias; Silvia Crescioli; Kerri Beckmann; Nga Le; Sophia N Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

2.  The Clinical, Pathological, and Prognostic Value of High PD-1 Expression and the Presence of Epstein-Barr Virus Reactivation in Patients with Laryngeal Cancer.

Authors:  Janusz Klatka; Anna Szkatuła-Łupina; Anna Hymos; Maria Klatka; Paulina Mertowska; Sebastian Mertowski; Ewelina Grywalska; Małgorzata Charytanowicz; Anna Błażewicz; Agata Poniewierska-Baran; Dominika Bębnowska; Paulina Niedźwiedzka-Rystwej
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.